Literature DB >> 20883364

Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis.

Tsutomu Ohtsuka1.   

Abstract

Systemic sclerosis (SSc) is a systemic connective tissue disease of unknown etiology which presents immunological, vascular and connective tissue abnormalities. Serum interleukin (IL)-6 has been reported to be elevated in patients with SSc. Clinical and laboratory findings affecting the elevated level of high-sensitivity C-reactive protein (hs-CRP) were studied in patients with SSc. Clinical and laboratory findings also included serum IL-6 level. Thirty-nine SSc patients (male : female = 7:32, age 19-84 years, mean 62.6 years) were studied. hs-CRP was measured with a nephelometric assay. Serum IL-6 level was measured by enzyme-linked immunosorbent assay. The distributions of hs-CRP showed that 18 cases (46.2%) were not elevated (<0.07 mg/dL), but 21 cases (53.8%) were (≥0.07 mg/dL). Alkaline phosphatase and IL-6 in SSc patients with elevated hs-CRP (291 ± 95 U/L, 3.23 ± 2.74 pg/mL) were significantly more elevated than those in not elevated patients (221 ± 75 U/L, 1.53 ± 1.12 pg/mL) (P < 0.02, P < 0.01). The correlation between hs-CRP level and IL-6 level in SSc patients was 0.687 (P < 0.001). In conclusion, elevated serum IL-6 levels are reflected in elevated hs-CRP levels in SSc patients.
© 2010 Japanese Dermatological Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20883364     DOI: 10.1111/j.1346-8138.2010.00883.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  10 in total

Review 1.  Protein Tyrosine Phosphatases in Systemic Sclerosis: Potential Pathogenic Players and Therapeutic Targets.

Authors:  Cristiano Sacchetti; Nunzio Bottini
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

Review 2.  Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.

Authors:  Anna Kowalska-Kępczyńska
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

3.  Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms.

Authors:  Stefan Schanz; Jörg Henes; Anja Ulmer; Ina Kötter; Gerhard Fierlbeck; C D Claussen; Marius Horger
Journal:  Eur Radiol       Date:  2012-07-29       Impact factor: 5.315

4.  Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?

Authors:  Xiaochun Liu; Maureen D Mayes; Claudia Pedroza; Hilda T Draeger; Emilio B Gonzalez; Brock E Harper; John D Reveille; Shervin Assassi
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-08       Impact factor: 4.794

5.  Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.

Authors:  L Grkovic; K Baird; S M Steinberg; K M Williams; D Pulanic; E W Cowen; S A Mitchell; F T Hakim; K J Martires; D N Avila; T N Taylor; R B Salit; S D Rowley; D Zhang; D H Fowler; M R Bishop; R E Gress; S Z Pavletic
Journal:  Leukemia       Date:  2011-10-18       Impact factor: 11.528

Review 6.  Interleukin-6: a new therapeutic target in systemic sclerosis?

Authors:  Steven O'Reilly; Rachel Cant; Marzena Ciechomska; Jacob M van Laar
Journal:  Clin Transl Immunology       Date:  2013-04-12

7.  Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis.

Authors:  Jakub Żółkiewicz; Anna Stochmal; Michał Zaremba; Lidia Rudnicka; Joanna Czuwara
Journal:  Postepy Dermatol Alergol       Date:  2019-04-26       Impact factor: 1.837

8.  Circulating biomarkers of interstitial lung disease in systemic sclerosis.

Authors:  Harpreet K Lota; Elisabetta A Renzoni
Journal:  Int J Rheumatol       Date:  2012-09-03

9.  Bank1 and NF-kappaB as key regulators in anti-nucleolar antibody development.

Authors:  Hammoudi Alkaissi; Said Havarinasab; Jesper Bo Nielsen; Peter Söderkvist; Per Hultman
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

Review 10.  Molecular Basis of Accelerated Aging with Immune Dysfunction-Mediated Inflammation (Inflamm-Aging) in Patients with Systemic Sclerosis.

Authors:  Chieh-Yu Shen; Cheng-Hsun Lu; Cheng-Han Wu; Ko-Jen Li; Yu-Min Kuo; Song-Chou Hsieh; Chia-Li Yu
Journal:  Cells       Date:  2021-12-02       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.